 | |
| Clinical data | |
|---|---|
| Trade names | Voquezna, others |
| AHFS/Drugs.com | Voquezna |
| MedlinePlus | a624006 |
| License data | |
| Routes of administration | By mouth |
| Drug class | Potassium-competitive acid blocker |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Unknown |
| Protein binding | 80% |
| Metabolism | Liver, bycytochrome P450 (3A4,2B6,2C19,2D6) |
| Eliminationhalf-life | 7.7 h |
| Duration of action | > 24 h |
| Excretion | Kidney |
| Identifiers | |
| CAS Number |
|
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI | |
| ChEMBL |
|
| PDB ligand | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H16FN3O2S |
| Molar mass | 345.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vonoprazan, sold under the brand nameVoquezna among others, is afirst-in-classpotassium-competitive acid blocker medication.[2][1] Vonoprazan is used in form of thefumarate for the treatment ofgastroduodenal ulcer (including some drug-induced peptic ulcers) and refluxesophagitis, and can be combined with antibiotics for the eradication ofHelicobacter pylori.[2]
It was approved in Japan in February 2015,[3][4] and in Russia in April 2021.[5] Vonoprazan was approved for medical use in the United States in November 2023.[1][6] Co-packaged combinations ofvonoprazan with amoxicillin andvonoprazan with amoxicillin and clarithromycin are available.[7][8]
Vonoprazan isindicated for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults; in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults; in combination with amoxicillin for the treatment of H. pylori infection in adults.[1][7][9]
In July 2024, the indication was expanded in the US to include non-erosive gastroesophageal reflux disease.[10]
The most common side effects are constipation, diarrhea,enlarged feeling of abdomen, nausea, rash, andedema.[1][11]
Long-term use may lead tovitamin B12 deficiency,hypomagnesemia, andfundic gland polyps.[11]
Vonoprazan is theinternational nonproprietary name (INN).[12]
